Tenax Therapeutics opened lower at $1.67, compared with its previous close of $1.69. In the last trading session, the stock traded between $1.60 and $1.68. It showed a downward intraday trend.
An investment of $100 made 5 years ago in Tenax Therapeutics is now worth
$ 0.07
Resulting in a loss of
$ 99.93 (99.93%)
Note: Past profits do not guarantee future returns.
Rating from 7 Analysts
Today's Change
$-0.09 (-5.03%)
Day High
$1.68
Day Low
$1.60
Day Open
$1.67
Prev Close
$1.69
Volume
6,75,738
1W Return
-10.93%
1M Return
-12.53%
3M Return
-0.50%
6M Return
-86.57%
1Y Return
-77.20%
Market Cap ($ Mn)
73
PE Ratio
-
PB Ratio
0.60
PEG Ratio
-
ROE
-52.82%
ROCE
-56.66%
EPS (TTM)
$-0.37
1 Week
-10.93%
1 Month
-12.53%
3 Months
-0.50%
6 Months
-86.57%
9 Months
-87.65%
Tenax Therapeutics lead plaintiff deadline set for December 28, 2026
Lead plaintiff deadline for Tenax Therapeutics securities class action is December 28, 2026. Class Period spans November 13, 2023 to August 7, 2026, during which ~$134 million was raised. Shares fell 89.77% after Phase 3 LEVEL trial missed primary endpoint. Allegations center on overstated TNX-103 regulatory and commercial prospects.
TodayTenax Therapeutics Q3 Results: Loss narrows 22.5% YoY to $0.31
Tenax Therapeutics reported a Q3 loss of $0.31 per share. The result beat the analyst consensus estimate of $0.40 by 20.51%. Losses narrowed by 22.5% compared to the $0.40 loss in the same quarter last year.
7 days agoTenax Therapeutics CEO to present at 2026 Cantor Global Healthcare Conference
Tenax Therapeutics CEO Chris Giordano to present at 2026 Cantor Global Healthcare Conference. Presentation scheduled for September 9, 2026, at 8:35 am ET. Live and archived webcast available on company investor relations page. Company developing levosimendan for PH-HFpEF treatment.
2mo agoTenax Therapeutics confirms TNX-103 subgroup efficacy in Phase 3 data
Tenax Therapeutics presented additional Phase 3 LEVEL trial data for TNX-103 at ESC 2026. Primary endpoint missed significance in overall population of 241 PH-HFpEF patients. Significant 26.3 meter improvement in 6MWD seen in subgroup with lower baseline walking distance. Therapy showed 47% reduction in NT-proBNP and 4.9 mmHg drop in RVSP in target subgroup. Company plans to enrich patient population for upcoming LEVEL-2 Phase 3 trial.
2mo agoSBS Law joins probes into Tenax Therapeutics after trial failure
Three law firms are investigating Tenax Therapeutics following the failure of its Phase 3 LEVEL trial for TNX-103. The drug missed primary endpoints, causing an 84% to 85% stock drop. Probes focus on whether prior statements about trial design and patient population were misleading.
2mo agoTenax Therapeutics stock dives 89% as heart drug trial misses primary endpoint
Tenax Therapeutics reported that its Phase 3 LEVEL trial for oral levosimendan missed primary endpoints in PH-HFpEF, causing shares to drop 89.49%. However, significant biomarker improvements and benefits in a severe disease subgroup offer potential pathways forward, prompting planned discussions with the FDA.
3mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $547.03 | -0.16% | $1,38,692.89M | 31.55 | |
| $61.05 | +0.38% | $1,31,510.31M | 14.39 | |
| $248.69 | -0.85% | $1,00,625.20M | - | |
| $959.41 | +4.73% | $97,505.80M | 19.64 | |
| $977.58 | +0.62% | $61,476.10M | 38.99 | |
| $419.98 | -0.95% | $46,108.31M | 65.60 | |
| $180.70 | -6.40% | $39,083.96M | - | |
| $53.87 | -0.37% | $33,618.11M | 26.24 | |
| $70.01 | +0.81% | $31,173.07M | 32.37 | |
| $41.85 | +1.60% | $30,322.88M | - | |
| $120.75 | +1.05% | $26,490.14M | - | |
| $122.27 | +1.64% | $24,922.54M | 15.85 |
An investment of $100 made 5 years ago in Tenax Therapeutics is now worth
$ 0.07
Resulting in a loss of
$ 99.93 (99.93%)
Note: Past profits do not guarantee future returns.
